Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety, Tolerability and Efficacy of ILB in Patients With Amyotrophic Lateral Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03613571
Recruitment Status : Enrolling by invitation
First Posted : August 3, 2018
Last Update Posted : September 20, 2018
Sponsor:
Information provided by (Responsible Party):
TikoMed AB

Brief Summary:

This is a Phase 2a single-centre, open single-arm study in patients with Amyotrophic Lateral Sclerosis (ALS) of intermediate progression rate. Eligible subjects will be administered weekly doses of ILB. A total of 5 subcutaneous (s.c.) doses will be administered at the study clinic.

The study consists of 10 visits; One 2-part screening visit, 5 ILB administration visits, and 3 follow-up visits. Each individual patient's study participation will be 4 months, including the screening and follow-up visits. Fifteen patients are planned to be included.

The primary objective of the study is to evaluate the safety and tolerability of ILB in patients diagnosed with ALS.

ILB is a solution for subcutaneous (s.c.) injection in saline solution. The dose administered will depend on the subject's body weight at the second study visit, prior to the first ILB administration.

No formal sample size calculation has been performed for this study. The proposed sample size is considered sufficient in this early phase 2 development to provide adequate information on the patients. Categorical data will be presented as counts and percentages. Continuous data will be summarised using descriptive statistics.


Condition or disease Intervention/treatment Phase
Amyotrophic Lateral Sclerosis Drug: ILB Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-centre, Open Single-arm Study Where the Safety, Tolerability and Efficacy of Subcutaneously Administered ILB Will be Evaluated in Patients With Amyotrophic Lateral Sclerosis
Actual Study Start Date : August 15, 2018
Estimated Primary Completion Date : June 1, 2019
Estimated Study Completion Date : June 1, 2019


Arm Intervention/treatment
Experimental: ILB
ILB treatment
Drug: ILB
The investigational medicinal product ILB will be given as single short-term s.c. injections in the abdomen, the thigh or the buttock, in that order of priority. Subjects will be observed for at least 3 hours after injection.The IMP is a sterile, colourless to pale yellow solution for subcutaneous injection.




Primary Outcome Measures :
  1. Frequency, seriousness and intensity of Treatment-emergent Adverse Events (TEAEs) [ Time Frame: up to 3 months ]

    A TEAE is any adverse event (AE) not present prior to the initiation of IMP administration or any event already present that worsens in either intensity or frequency following exposure to the IMP. AEs (including baseline events) identified using any of the following methods will be recorded:

    • AEs spontaneously reported by the subject
    • AEs observed by the Investigator or medical personnel
    • AEs elicited based on non-leading questions from the Investigator or medical personnel

  2. Change in physical status [ Time Frame: up to 3 months ]

    A complete physical examination according to clinical praxis will be performed, including assessment of the head, eyes, ears, nose, throat (EENT), cardiac, peripheral vascular, pulmonary, musculoskeletal, neurologic, abdominal, lymphatic and dermatological functions.

    According to clinical praxis each function is judged as either normal or abnormal, and either clinically significant (CS) or not clinically significant (NCS)

    Change from baseline at 3 months.


  3. Change in vital signs - blood pressure [ Time Frame: up to 3 months ]
    Percent change in blood pressure (mmHg) from baseline at 3 months

  4. Change in electrocardiogram (ECG) recordings [ Time Frame: up to 3 months ]
    Change in single 12-lead ECG (PQ/PR (ms), QRS (ms), QT (ms) and QTcF (ms)) from baseline at 3 months

  5. Change in vital signs - heart rate [ Time Frame: up to 3 months ]
    Percent change in heart rate (bpm, beats per minute) from baseline at 3 months

  6. Change in vital signs - body temperatue [ Time Frame: up to 3 months ]
    Percent change in body temperature (degrees Celsius) from baseline at 3 months

  7. Change in safety laboratory measurements - sodium, potassium, chloride, calcium, glucose (non-fasting) [ Time Frame: up to 3 months ]

    According to clinical praxis, laboratory tests for sodium, potassium, chloride, calcium, glucose (non-fasting) will be analysed. Unit of measure is mmol/L

    According to clinical praxis each function is judged as either normal or abnormal, and either clinically significant (CS) or not clinically significant (NCS)

    Change from baseline at 3 months.


  8. Change in safety laboratory measurements - albumin [ Time Frame: up to 3 months ]

    According to clinical praxis, laboratory test for albumin will be analysed. Unit of measure is g/L

    According to clinical praxis each function is judged as either normal or abnormal, and either clinically significant (CS) or not clinically significant (NCS)

    Change from baseline at 3 months.


  9. Change in safety laboratory measurements - AST, ALT, CK, alkaline phosphatase [ Time Frame: up to 3 months ]

    According to clinical praxis, laboratory tests for aspartate amino-transferase (AST), alanine amino-transferase (ALT), creatine kinase (CK) and alkaline phosphatase will be analysed. Unit of measure is micro-kat/L

    According to clinical praxis each function is judged as either normal or abnormal, and either clinically significant (CS) or not clinically significant (NCS)

    Change from baseline at 3 months.


  10. Change in safety laboratory measurements - creatinine and total bilirubin [ Time Frame: up to 3 months ]

    According to clinical praxis, laboratory tests for creatinine and total bilirubin will be analysed. Unit of measure is micro-mol/L

    According to clinical praxis each function is judged as either normal or abnormal, and either clinically significant (CS) or not clinically significant (NCS)

    Change from baseline at 3 months.


  11. Change in safety laboratory measurements - myoglobin [ Time Frame: up to 3 months ]

    According to clinical praxis, laboratory test for myoglobin will be analysed. Unit of measure is micro-g/L

    According to clinical praxis each function is judged as either normal or abnormal, and either clinically significant (CS) or not clinically significant (NCS)

    Change from baseline at 3 months.


  12. Change in safety laboratory measurements - CRP [ Time Frame: up to 3 months ]

    According to clinical praxis, laboratory test for C-reactive protein (CRP) will be analysed. Unit of measure is milli-g/L

    According to clinical praxis each function is judged as either normal or abnormal, and either clinically significant (CS) or not clinically significant (NCS)

    Change from baseline at 3 months.


  13. Change in hematology laboratory measurements - Hemoglobin and fibrinogen [ Time Frame: up to 3 months ]

    According to clinical praxis, laboratory tests for hemoglobin (Hb) and fibrinogen will be analysed. Unit of measure is g/L

    According to clinical praxis each function is judged as either normal or abnormal, and either clinically significant (CS) or not clinically significant (NCS)

    Change from baseline at 3 months.


  14. Change in hematology laboratory measurements - Red blood cell count [ Time Frame: up to 3 months ]

    According to clinical praxis, laboratory test for blood cell count (RBC) will be analysed. Unit of measure is 10x12/L

    According to clinical praxis each function is judged as either normal or abnormal, and either clinically significant (CS) or not clinically significant (NCS)

    Change from baseline at 3 months.


  15. Change in hematology laboratory measurements - WBC, platelets, basophils, eosinophils, lymphocytes, monocytes, neutrophils [ Time Frame: up to 3 months ]

    According to clinical praxis, laboratory tests for white blood cell count (WBC), platelets, basophils, eosinophils, lymphocytes, monocytes and neutrophils will be analysed. Unit of measure is 10x9/L

    According to clinical praxis each function is judged as either normal or abnormal, and either clinically significant (CS) or not clinically significant (NCS)

    Change from baseline at 3 months.


  16. Change in hematology laboratory measurements - APTT [ Time Frame: up to 3 months ]

    According to clinical praxis, laboratory test for activated partial thromboplastin time (aPTT) will be analysed. Unit of measure is s

    According to clinical praxis each function is judged as either normal or abnormal, and either clinically significant (CS) or not clinically significant (NCS)

    Change from baseline at 3 months.


  17. Change in hematology laboratory measurements - PK-INR [ Time Frame: up to 3 months ]

    According to clinical praxis, laboratory test for prothrombin kinase international normalized ratio (PK-INR) will be analysed. Unitless measure

    According to clinical praxis each function is judged as either normal or abnormal, and either clinically significant (CS) or not clinically significant (NCS)

    Change from baseline at 3 months.



Secondary Outcome Measures :
  1. Change in functional rating with Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) [ Time Frame: up to 3 months ]

    The ALSFRS-R provides a physician-generated estimate of the patient's degree of functional impairment, which can be evaluated serially to objectively assess any response to treatment or progression of disease. The ALSFRS-R includes questions that ask the physician to rate his/her impression of the patients level of functional impairment in performing one of twelve common tasks. Each task is rated on a five-point scale from 0 = can't do, to 4 = normal ability. Individual item scores are summed to produce a reported score of between 0=worst and 48=best

    Absolute change from baseline at 3 months


  2. Change in functional rating with Norris rating scale [ Time Frame: up to 3 months ]

    The Norris rating scale provides a physician-generated estimate of the patient's degree of functional impairment, which can be evaluated serially to objectively assess any response to treatment or progression of disease. The Norris rating scale includes questions that ask the physician to rate his/her impression of the patients level of functional impairment in performing one of 34 common tasks and bodily functions. Each task or function is rated on a four-point scale from 0 = can't do, to 3 = normal ability. Individual item scores are summed to produce a reported score of between 0=worst and 100=best

    Absolute change from baseline at 3 months


  3. Change in pulmonary function (FVC) from baseline [ Time Frame: up to 3 months ]
  4. Change in Quality of Life (QoL) assessed by visual analogue scale (VAS) [ Time Frame: up to 1.5 months ]

    Questionnaire with three questions for patient and next-of-kin self reporting of:

    • general health status
    • physical health status
    • mental health status

    Each item is rated on a millimeter scale from 0 = very bad, to 100 = very good

    Absolute change from baseline at 3 months


  5. Change in functional rating of autonomous and sensory symptoms [ Time Frame: up to 3 months ]

    The autonomous and sensory rating scale provides a physician-generated estimate of the patient's degree of functional impairment, which can be evaluated serially to objectively assess any response to treatment or progression of disease. The rating scale includes questions that ask the physician to rate his/her impression of the patients level of impairment in 16 autonomous and sensory functions. Each function is rated on a four-point scale from 0 = not impaired, to 3 = very impaired.

    Absolute change from baseline at 3 months


  6. Change in maximum plasma concentration (Cmax) of ILB [ Time Frame: up to 1 month ]
  7. Change in exposure (Area Under the Curve, AUC) of ILB [ Time Frame: up to 1 month ]
  8. Changes in APTT (effect APTT) from day of dosing (day 1) [ Time Frame: up to 1 month ]
  9. Change in plasma concentration of hepatocyte growth factor (HGF) [ Time Frame: up to 1 month ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Willing and able to give written informed consent for participation in the study.
  2. Clinical diagnosis of Amyotrophic Lateral Sclerosis (ALS).
  3. Male or female patients between 18 to 80 years (inclusive).
  4. Forced Vital Capacity (FVC) 65% of predicted value for gender, height and age at screening.
  5. Evaluated with ALSFRS-R and Norris clinical rating scales for at least the past 4 weeks before study drug administration.
  6. Laboratory analyses within normal ranges for PK-INR, fibrinogen von Willebrand factor and activated partial thromboplastin time (APTT) at screening.

Exclusion criteria

  1. Unable to understand information about the study or are expected not to collaborate with the study team.
  2. Concurrent serious disease, other than ALS.
  3. Pregnancy.
  4. Patients of child-bearing potential not willing to use adequate double contraception with <1% failure rate after the screening visit until the last visit.
  5. Addiction to drugs or alcohol.
  6. Confirmed HIV, hepatitis B or hepatitis C.
  7. Known bleeding disorders or abnormal bleeding events.
  8. Treatment with anticoagulant drugs warfarin and novel oral anticoagulants (NOAC) within the last 14 days prior to screening.
  9. Treatment with Riluzole or Lamotrigine within the last 28 days prior to study drug administration.
  10. Hypersensitivity to dextran sulfate.
  11. Poor venous access

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03613571


Locations
Layout table for location information
Sweden
Sahlgrenska University Hospital
Gothenburg, Sweden
Sponsors and Collaborators
TikoMed AB

Layout table for additonal information
Responsible Party: TikoMed AB
ClinicalTrials.gov Identifier: NCT03613571     History of Changes
Other Study ID Numbers: 1.3, 2018-08-23
First Posted: August 3, 2018    Key Record Dates
Last Update Posted: September 20, 2018
Last Verified: September 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Sclerosis
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases